pagibaximab

INTRODUCTION Advances in modern medicine have given very low birth weight (VLBW) infants a better chance of survival; however… Expand

BACKGROUND Pagibaximab, a human chimeric monoclonal antibody developed against lipoteichoic acid, was effective against… Expand

Staphylococcal sepsis is a major cause of morbidity and mortality in very-low-birth-weight (VLBW) infants. A human chimeric… Expand

A chimerized (murine/human) monoclonal antibody (pagibaximab) against lipoteichoic acid (LTA) and protective in animal models for… Expand

BACKGROUND Nosocomial infection is a major problem affecting the immediate health and long-term outcome of preterm and very low… Expand

The ability to measure the opsonic activity of antibody may be critical in choosing among potential therapeutic candidates. It… Expand

Staphylococci, especially coagulase negative staphylococci (CONS), are responsible for over 75 % of late-onset infections in very… Expand